1.
Leukostasis as a result of rapidly progressive granulocytosis in a patient diagnosed with MDS/MPN-U.
Blood
; 134(23): 2117, 2019 12 05.
Article
in English
| MEDLINE
| ID: mdl-31805197
Subject(s)
Bone Marrow , Hematologic Neoplasms , Hydroxyurea/administration & dosage , Leukostasis , Myelodysplastic-Myeloproliferative Diseases , Pyrazoles/administration & dosage , Aged , Bone Marrow/metabolism , Bone Marrow/pathology , Fatal Outcome , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/metabolism , Hematologic Neoplasms/pathology , Humans , Leukostasis/drug therapy , Leukostasis/metabolism , Leukostasis/pathology , Male , Myelodysplastic-Myeloproliferative Diseases/drug therapy , Myelodysplastic-Myeloproliferative Diseases/metabolism , Myelodysplastic-Myeloproliferative Diseases/pathology , Nitriles , Pyrimidines
2.
Leuk Res Rep
; 7: 6-10, 2017.
Article
in English
| MEDLINE
| ID: mdl-28066705
ABSTRACT
Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.
